DNA can sustain serious injuries called double strand breaks, in which both strands of the helix snap. These breaks are among the most dangerous forms of DNA damage and immediately trigger the cell's ...
Getting something for nothing is rare these days, but O2 is bucking the trend this December. The popular UK mobile network - which is now part of Virgin Media - is spreading some serious festive cheer ...
Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome, supporting a bullish outlook. KYTX's Miv-cel achieved significant clinical improvements and ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
WASHINGTON — A defense policy bill expected to be voted on this week does not include provisions that would have ensured the military’s ability to purchase the technical data, parts and information ...
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two ...
– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to ...
ORLANDO, Fla.—The leader of Gilead Sciences' Kite Pharma is sure that anito-cel, the biotech’s next-generation multiple myeloma CAR-T challenger to Carvykti, is ready for prime time—and that the ...
The human body operates on a roughly 24-hour cycle known as the circadian rhythm. The cycle is primarily controlled by the suprachiasmatic nucleus — two clusters of neurons in the hypothalamus. This ...
The Terrain Commander from Textron Corporation provides the basis for the U.S. Army's unattended ground sensor (UGS) Future Combat Systems. The sensor assembly is equipped with a variety of optical, ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.